Skip to main content
European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary
Contenido archivado el 2024-05-24

Heparanase inhibitors in antiangiogenic and antimetastatic cancer therapy

Objetivo

Inhibition of heparanase overexpressed by tumours, preventing not only the release and activation of angiogenic growth factors stored by heparan sulfate (HS) proteoglycans but also the disruption of the basement membrane and the extracellular matrix is regarded as a very promising strategy to develop anticancer drugs. This project aims at:
a) mapping the binding sites of heparanase for HS;
b) determining the structural requirements of HS-like polysaccharides for interaction with the enzyme as substrates and as inhibitors;
c) improving the heparanase-inhibiting properties of polysaccharides by generating specific sulfation patterns optimised on biological activity (inhibition of heparanase, antimetastatic-antiangiogenic activity).

These aims will be pursued through a study of the inhibition of heparanase with natural and synthetic HS-like oligo/polysaccharides, glycomimetics, and its in vivo effects.

Convocatoria de propuestas

Data not available

Régimen de financiación

CSC - Cost-sharing contracts

Coordinador

ISTITUTO SCIENTIFICO DI CHIMICA E BIOCHIMICA "G.RONZONI"
Aportación de la UE
Sin datos
Dirección
Via Giuseppe Colombo 81
20133 MILANO
Italia

Ver en el mapa

Coste total
Sin datos

Participantes (6)